CPI-1612
CPI-1612 is a highly potent, orally active EP300/CBP histone acetyltransferase (HAT) inhibitor with an IC50 of 8.1 nM for EP300 HAT. CPI-1612 has an anticancer activity[1].
Product Specifications
CAS Number
[2374971-81-8]
UNSPSC
12352005
Target
Histone Acetyltransferase
Type
Reference compound
Related Pathways
Epigenetics
Applications
Cancer-programmed cell death
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/p300-cbp-in-6.html
Purity
99.74
Solubility
DMSO : 230 mg/mL (ultrasonic)
Smiles
O=C(NC1=NC=C(C2=CN(C)N=C2)C=C1)[C@H](NC[C@H](C3=CC=C(C#N)C=C3)C)C4=CC=CC=C4
Molecular Formula
C27H26N6O
Molecular Weight
450.53
References & Citations
[1]Jonathan E Wilson, et al. Discovery of CPI-1612: A Potent, Selective, and Orally Bioavailable EP300/CBP Histone Acetyltransferase Inhibitor. ACS Med Chem Lett. 2020 Apr 23;11 (6) :1324-1329.
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Isoform
CBP/p300
Available Sizes
Curated Selection
Explore Other Products
Discover premium biology products from our extensive collection of 20M+ items
GTR15127367 1 Vial
Lentiviral human ARL4D shRNA (UAS) - Lentiviral human ARL4D shRNA (UAS, RFP) (25)
Ask
View Details